S-(+)-Marmesin ((+)-Marmesin)
(Synonyms: 异紫花前胡内酯,(+)-Marmesin; (S)-Marmesin) 目录号 : GC30027A coumarin with anticancer activity
Cas No.:13849-08-6
Sample solution is provided at 25 µL, 10mM.
Marmesin is a coumarin originally isolated from the mature bark of A. marmelos.1 Marmesin decreases proliferation and cell invasion induced by fetal bovine serum (FBS) in H1299 non-small cell lung cancer cells (NSCLCs) when used at a concentration of 10 ?M.2 It decreases VEGF secretion in A549 and H1299 cells and inhibits capillary-like structure formation by human umbilical vein endothelial cells (HUVECs). Marmesin also decreases proliferation of U937 human leukemia cells (IC50 = 40 ?M).3 It halts the cell cycle at the G2/M phase, increases the ratio of Bax to Bcl-2 protein, induces apoptosis, and inhibits cell migration. Marmesin reduces tumor growth in a U937 mouse xenograft model when administered at a dose of 30 mg/kg.
1.Chatterjee, A., and Mitra, S.S.On the constitution of the active principles isolated from the mature bark of Aegle marmelos, Corre?J. Am. Chem. Soc.71(2)606-609(1949) 2.Kim, J.H., Kim, M.S., Lee, B.H., et al.Marmesin-mediated suppression of VEGF/VEGFR and integrin β1 expression: Its implication in non-small cell lung cancer cell responses and tumor angiogenesisOncol. Rep.37(1)91-97(2017) 3.Dong, L., Xu, W.W., Li, H., et al.In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrial-mediated apoptosis, cell cycle arrest, and inhibition of cancer cell migrationOncol. Rep.39(2)597-602(2018)
Cas No. | 13849-08-6 | SDF | |
别名 | 异紫花前胡内酯,(+)-Marmesin; (S)-Marmesin | ||
Canonical SMILES | O=C1C=CC2=CC3=C(O[C@H](C(C)(O)C)C3)C=C2O1 | ||
分子式 | C14H14O4 | 分子量 | 246.26 |
溶解度 | DMSO : 2 mg/mL (8.12 mM) | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.0607 mL | 20.3037 mL | 40.6075 mL |
5 mM | 0.8121 mL | 4.0607 mL | 8.1215 mL |
10 mM | 0.4061 mL | 2.0304 mL | 4.0607 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet